ES2571032T3 - Composiciones de itraconazol con biodisponibilidad mejorada - Google Patents

Composiciones de itraconazol con biodisponibilidad mejorada

Info

Publication number
ES2571032T3
ES2571032T3 ES06776678T ES06776678T ES2571032T3 ES 2571032 T3 ES2571032 T3 ES 2571032T3 ES 06776678 T ES06776678 T ES 06776678T ES 06776678 T ES06776678 T ES 06776678T ES 2571032 T3 ES2571032 T3 ES 2571032T3
Authority
ES
Spain
Prior art keywords
improved bioavailability
itraconazole
δhtr
itraconazole compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06776678T
Other languages
English (en)
Inventor
Gunther Berndl
Matthias Degenhardt
Markus Mägerlein
Gerrit Dispersyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
Barrier Therapeutics Inc
Original Assignee
AbbVie Deutschland GmbH and Co KG
Barrier Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Deutschland GmbH and Co KG, Barrier Therapeutics Inc filed Critical AbbVie Deutschland GmbH and Co KG
Application granted granted Critical
Publication of ES2571032T3 publication Critical patent/ES2571032T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un producto de dispersión sólida, que se puede obtener mediante un proceso de extrusión por fundido, que comprende itraconazol e hidroxipropilmetilcelulosa, que satisface la fórmula 0,35 > ΔHtr (en donde ΔHtr representa la endotermia (J/g) que acompaña a una transición a una temperatura pico endotérmica en el intervalo de desde 240 ºC a 250 ºC).
ES06776678T 2005-08-08 2006-08-08 Composiciones de itraconazol con biodisponibilidad mejorada Active ES2571032T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59581605P 2005-08-08 2005-08-08
PCT/EP2006/007839 WO2007017248A2 (en) 2005-08-08 2006-08-08 Itraconazole compositions with improved bioavailability

Publications (1)

Publication Number Publication Date
ES2571032T3 true ES2571032T3 (es) 2016-05-23

Family

ID=37727665

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06776678T Active ES2571032T3 (es) 2005-08-08 2006-08-08 Composiciones de itraconazol con biodisponibilidad mejorada

Country Status (6)

Country Link
US (2) US8486456B2 (es)
EP (1) EP1912625B1 (es)
JP (2) JP5538718B2 (es)
CA (1) CA2618255C (es)
ES (1) ES2571032T3 (es)
WO (1) WO2007017248A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017249A1 (en) 2005-08-08 2007-02-15 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
JP5538718B2 (ja) * 2005-08-08 2014-07-02 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつイトラコナゾール組成物
CA2836579A1 (en) * 2011-05-19 2012-11-22 Rfs Pharma, Llc Purine monophosphate prodrugs for treatment of viral infections
KR20200065093A (ko) * 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
US9763934B2 (en) * 2014-03-05 2017-09-19 Professional Compounding Centers Of America Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast
WO2015134822A1 (en) * 2014-03-05 2015-09-11 Professional Compounding Centers Of America Poloxamer-based pharmaceutical compositions for treating wounds
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
RU2127733C1 (ru) 1992-03-18 1999-03-20 Жансен Фармасетика Н.В. Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и фармацевтическая композиция на их основе
WO1997044014A1 (en) * 1996-05-20 1997-11-27 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
WO2002024168A1 (fr) * 2000-09-25 2002-03-28 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide medicinale
CN101480384A (zh) 2002-12-17 2009-07-15 阿伯特有限及两合公司 包含非诺贝酸、其生理可接受的盐或衍生物的制剂
WO2004056359A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2007017249A1 (en) 2005-08-08 2007-02-15 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
JP5538718B2 (ja) * 2005-08-08 2014-07-02 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつイトラコナゾール組成物

Also Published As

Publication number Publication date
WO2007017248A3 (en) 2007-05-31
JP2014062110A (ja) 2014-04-10
JP5763735B2 (ja) 2015-08-12
CA2618255C (en) 2015-05-26
US8486456B2 (en) 2013-07-16
EP1912625A2 (en) 2008-04-23
EP1912625B1 (en) 2016-04-13
JP2009504589A (ja) 2009-02-05
WO2007017248A2 (en) 2007-02-15
US9149431B2 (en) 2015-10-06
CA2618255A1 (en) 2007-02-15
US20140005204A1 (en) 2014-01-02
JP5538718B2 (ja) 2014-07-02
US20090214656A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
WO2007031548A3 (en) Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof
AR064165A1 (es) Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
GT200600213A (es) Metodos para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios
AR059122A1 (es) Produccion de olefinas livianas a traves de dimetileter
MX2007005933A (es) Compuestos de acetamida como fungicidas.
SG10201811715YA (en) Intermediates and methods for the synthesis of halichondrin b analogs
CY1109854T1 (el) Παραγωγα αζαδικυκλο(3.1.0)εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
WO2009019015A8 (en) Novel herbicides
TN2011000286A1 (en) Spiroheterocyclic n-oxypiperidines as pesticides
MX2009013276A (es) Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
ATE522577T1 (de) Thermoplastische polyamide mit polyetheraminen
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
CY1118173T1 (el) 5-[(3,3,3-τριφθορο-2-υδροξυ-1-αρυλπροπυλ)αμινο]-1h-κινολιν-2-ονες, μια διεργασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδων παραγοντων
CY1111954T1 (el) Παραγωγα τετραϋδροναφθαλινιου, μεθοδοι για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδη
ES2571032T3 (es) Composiciones de itraconazol con biodisponibilidad mejorada
ATE402173T1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
ITMI20050801A1 (it) Procedimento per la preparazione di telmisartan
EP4388876A3 (en) Fungicidal nitroanilino substituted pyrazoles
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MX2010002470A (es) Derivados de dimetilciclohexilo como neutralizadores de malos olores.
WO2009030450A8 (en) Novel herbicides
DE602006010584D1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
ATE479688T1 (de) Herstellung von famciclovir und anderen purinderivaten